DeepLook Medical Advances Commercialization of DL Precise™ Across Major Healthcare Institutions Nationwide

Company expands national presence with DL Precise™ and launches new clinical studies

Phoenix, AZ - DeepLook Medical, a company advancing medical imaging through visual enhancement technology, today announced that its flagship product, DL Precise™, is now in commercial use at major healthcare institutions across the United States, including Cleveland Clinic, AdventHealth, Mayo Clinic, Geisinger, and others.

This milestone marks the continuation of DeepLook’s commercial rollout, following successful pilots and initial data confirming the platform’s potential to support clinical performance and streamline imaging workflows.

“The commercial adoption of DL Precise™ at major institutions across the country marks a pivotal moment for DeepLook Medical. These installations reflect not only a growing demand for enhanced imaging precision but also confidence in the value we’re delivering, especially in areas where traditional imaging falls short. As we expand into new modalities and strengthen our evidence base, we remain focused on scaling global access and redefining how providers approach cancer detection by using artificial intelligence.” said Marissa Fayer, CEO of DeepLook Medical.

DL Precise™ integrates directly into radiology workstations and overlays on existing imaging systems.  By using proprietary shape-recognition AI software, it provides single-click segmentation and enhanced visualization of suspicious lesions - particularly helpful in dense breast tissue. The platform is currently compatible with multiple imaging modalities, including mammography, ultrasound, CT, and MRI, and is now expanding into broader use in ultrasound.

To further evaluate the impact of DL Precise™ on diagnostic performance and operational benchmarks, evidence-generation studies are now underway in the U.S., U.K., and Israel. These efforts build on promising retrospective data from a New York metropolitan hospital, where use of the software was associated with a 12% improvement in recall performance aligned with American College of Radiology guidelines.

“Healthcare systems around the world are proactively embracing AI not just as a future promise, but as a present-day solution to long-standing diagnostic challenges. With DL Precise™, we’re seeing firsthand how intelligent imaging can immediately enhance clinical decision-making, reduce variability, and bring clarity to some of the most complex cases, especially in dense tissue where traditional tools often fall short. This is AI in action, delivering real-time value at the point of care.” said Charlotte Owens, MD, FACOG, Chief Medical Officer of DeepLook Medical

DeepLook Medical’s commercial growth is supported by a network of distribution partners, including Barco, and strong investor backing. Continued support from existing and new investors, including Arizona Venture Capital Inc., has enabled DeepLook’s recent relocation to Arizona, positioning the company to scale its commercial and clinical reach.

About DeepLook Medical

DeepLook Medical focuses on visual enhancement technology to advance medical imaging. DL Precise™ is the first in a series of innovative products using the company’s unique shape-recognition software to delineate the details of tumor morphology – a key to better diagnosis and treatment across the field of oncology. The company is leveraging other complementary AI advances to further the reach and impact of its patented technology. To learn more, please visit: https://www.deeplookmedical.com/